Home >> Products & Services >> Plasmids in Stock

pMD2.G

Catalog Number P0262
Alternative Names DB00002;VSVG,慢病毒2代3质粒包装质粒
Select Format
Quantity
Lead Time
In Stock
Price: Request a Quote
Contact us

Product Information

Plasmid NamepMD2.GAlternative NamesDB00002;VSVG,慢病毒2代3质粒包装质粒
PromoterCMVRepliconpUC
Copy NumberhighCompetent CellDH5a
Culture Temp37°CForward PrimerCMV-F:CGCAAATGGGCGGTAGGCGTG
Reverse PrimerForward(left ITR):CCTCTGACTTGAGCGTCGATStorage Temp37°C

Product Overview

Product Documents

No related files available.

Product Disclaimer

1.For Research Use Only

All products available through the MiaoLing Plasmid Platform are intended for research use only. They are not intended for clinical trials or for use in humans, including oral administration, injection, or therapeutic use in vivo or ex vivo.

2.Plasmid Sequence and Experimental Performance

Plasmid products are provided and sold based on the corresponding reference/template plasmid. MiaoLing guarantees the accuracy of the specified gene sequence based on our sequencing results, but does not guarantee downstream experimental performance, including gene expression, transfection efficiency, protein expression, or other experimental outcomes.

3.Sequence Verification of Certain Vector Products

For certain vector products, even the original manufacturer may not have fully verified the complete plasmid sequence. If the sequence of the key functional regions has been confirmed to be correct, the product will be considered a correct and usable vector for research purposes.

4.After-Sales Period for Small-Pack Plasmid Products

The after-sales service period for small-pack plasmid products is three months from the date of receipt. Customers are advised to transform and process the plasmid promptly after receipt. After the three-month period, a new purchase may be required for further support or replacement.

5.Research-Related Risks and Limitation of Liability

Scientific research is inherently exploratory and involves a significant degree of uncertainty. To the maximum extent permitted by applicable law, MiaoLing shall not be liable for any additional economic losses, indirect losses, or other liabilities arising from the use of our products or from research outcomes.

6.Citation in Chinese Publications

For publications in Chinese, please cite the product as follows:

7.Product Name (Product Item Number) was provided by the MiaoLing Plasmid Platform.

Citation in English Publications

For publications in English, please cite the product as follows:

“Product Name (Product Item Number) was obtained from MiaoLing Plasmid, China.”

Plasmid Sequence

TGGAGGCAAGGCCTGCAAAATGCAATACTGCAAGCATTGGGGAGTCAGACTCCCATCAGGTGTCTGGTTCGAGATGGCTGATAAGGATCTCTTTGCTGCAGCCAGATTCCCTGAATGCCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAGACCTCAGTGGATGTAAGTCTAATTCAGGACGTTGAGAGGATCTTGGATTATTCCCTCTGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCTTCCAATCTCTCCAGTGGATCTCAGCTATCTTGCTCCTAAAAACCCAGGAACCGGTCCTGCTTTCACCATAATCAATGGTACCCTAAAATACTTTGAGACCAGATACATCAGAGTCGATATTGCTGCTCCAATCCTCTCAAGAATGGTCGGAATGATCAGTGGAACTACCACAGAAAGGGAACTGTGGGATGACTGGGCACCATATGAAGACGTGGAAATTGGACCCAATGGAGTTCTGAGGACCAGTTCAGGATATAAGTTTCCTTTATACATGATTGGACATGGTATGTTGGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTGTTCGAACATCCTCACATTCAAGACGCTGCTTCGCAACTTCCTGATGATGAGAGTTTATTTTTTGGTGATACTGGGCTATCCAAAAATCCAATCGAGCTTGTAGAAGGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCCTCTTTTTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTCTCCGAGTTGGTATCCATCTTTGCATTAAATTAAAGCACACCAAGAAAAGACAGATTTATACAGACATAGAGATGAACCGACTTGGAAAGTAACTCAAATCCTGCACAACAGATTCTTCATGTTTGGACCAAATCAACTTGTGATACCATGCTCAAAGAGGCCTCAATTATATTTGAGTTTTTAATTTTTATGAAAAAAAAAAAAAAAAACGGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAATGATGTATTTAAATTATTTCTGAATATTTTACTAAAAAGGGAATGTGGGAGGTCAGTGCATTTAAAACATAAAGAAATGAAGAGCTAGTTCAAACCTTGGGAAAATACACTATATCTTAAACTCCATGAAAGAAGGTGAGGCTGCAAACAGCTAATGCACATTGGCAACAGCCCCTGATGCCTATGCCTTATTCATCCCTCAGAAAAGGATTCAAGTAGAGGCTTGATTTGGAGGTTAAAGTTTTGCTATGCTGTATTTTACATTACTTATTGTTTTAGCTGTCCTCATGAATGTCTTTTCACTACCCATTTGCTTATCCTGCATCTCTCAGCCTTGACTCCACTCAGTTCTCTTGCTTAGAGATACCACCTTTCCCCTGAAGTGTTCCTTCCATGTTTTACGGCGAGATGGTTTCTCCTCGCCTGGCCACTCAGCCTTAGTTGTCTCTGTTGTCTTATAGAGGTCTACTTGAAGAAGGAAAAACAGGGGGCATGGTTTGACTGTCCTGTGAGCCCTTCTTCCCTGCCTCCCCCACTCACAGTGACCCGGAATCCCTCGACATGGCAGTCTAGCACTAGTGCGGCCGCAGATCTGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTGGATCCCCTGAGGGGGCCCCCATGGGCTAGAGGATCCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGAGCTTGGCCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCCCTCGAAGCTTACATGTGGTACCGAGCTCGGATCCTGAGAACTTCAGGGTGAGTCTATGGGACCCTTGATGTTTTCTTTCCCCTTCTTTTCTATGGTTAAGTTCATGTCATAGGAAGGGGAGAAGTAACAGGGTACACATATTGACCAAATCAGGGTAATTTTGCATTTGTAATTTTAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAATACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACCATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTCTGCATATAAATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGCACGTGAGATCTGAATTCTGACACTATGAAGTGCCTTTTGTACTTAGCCTTTTTATTCATTGGGGTGAATTGCAAGTTCACCATAGTTTTTCCACACAACCAAAAAGGAAACTGGAAAAATGTTCCTTCTAATTACCATTATTGCCCGTCAAGCTCAGATTTAAATTGGCATAATGACTTAATAGGCACAGCCTTACAAGTCAAAATGCCCAAGAGTCACAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCCAAATGGGTCACTACTTGTGATTTCCGCTGGTATGGACCGAAGTATATAACACATTCCATCCGATCCTTCACTCCATCTGTAGAACAATGCAAGGAAAGCATTGAACAAACGAAACAAGGAACTTGGCTGAATCCAGGCTTCCCTCCTCAAAGTTGTGGATATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCCAGGTGACTCCTCACCATGTGCTGGTTGATGAATACACAGGAGAATGGGTTGATTCACAGTTCATCAACGGAAAATGCAGCAATTACATATGCCCCACTGTCCATAACTCTACAACCTGGCATTCTGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATTTCCATGGACATCACCTTCTTCTCAGAGGACGGAGAGCTATCATCCCTGGGAAAGGAGGGCACAGGGTTCAGAAGTAACTACTTTGCTTATGAAAC

Related Publications

1、 Xing Chang; Jingang Liu; Qian Yang; Yu Gao; Xiaofei Ding; Junjun Zhao; Yang Li; Zi Liu; Zengqiang Li; Yingliang Wu; Daiying Zuo,Targeting HMGA1 contributes to immunotherapy in aggressive breast cancer while suppressing EMT,2023-5-4,DOI:10.1016/j.bcp.2023.115582,(IF:5.3)
2、 Jirong Wang;Xiaoran Li;Siyu Chen;Jinlong Cao;Xinpeng Fan;Huabin Wang;Xingxing Zhang;Li Yang,Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis,2023-11-10,DOI:10.1016/j.lfs.2023.122253,(IF:5.2)
3、 Chunlei Li; Lilong Zhang; Yao Xu; Dongqi Chai; Shengchen Nan; Zhendong Qiu; Weixing Wang; Wenhong Deng,The prognostic significance and potential mechanism of prolyl 3-hydroxylase 1 in hepatocellular carcinoma,2022-10-26,DOI:10.1155/2022/7854297,(IF:0)
4、 Yang Zhou;Hui Yan;Qiang Zhou;Penggao Wang;Fang Yang;Ziqiao Yuan;Qianming Du;Bo Zhai,CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of MYCN-amplificated neuroblastoma,2023-7-5,DOI:10.1002/ctm2.1328,(IF:7.9)
5、 Qianwu Huang;Jun Lv;Ting Dong;Haijun Liu;Lei Xu;Mingcai Wu,Cryptochrome 1 alleviates the antiproliferative effect of isoproterenol on human gastric cancer cells,2020-6-1,DOI:10.1177/1559325820939022,(IF:2.3)
6、 Haixiao Duan; Ershuai Zhang; Ge Ren; Yining Cheng; Binfeng Yang; Lirong Liu; Normand Jolicoeur; Han Hu; Yan Xu; Binlei Liu,Exploring immune evasion of SARS-CoV-2 variants using a pseudotyped system,2024-4-18,DOI:10.1016/j.heliyon.2024.e29939,(IF:3.4)
7、 Peng Xu; Siyang Li; Ke Liu; Rui Fan; Fahui Liu; Haoxuan Zhang; Donghua Liu; Dongyan Shen,Downregulation of dermatopontin in cholangiocarcinoma cells suppresses CCL19 secretion of macrophages and immune infiltration,2024-2-1,DOI:10.1007/s00432-023-05532-1,(IF:2.7)
8、 Zihao Mai; Han Sun; Fangfang Yang; Mengyan Du; Xuecheng Cheng; Hongce Chen; Beini Sun; Junlin Wen; Xiaoping Wang; Tongsheng Chen,Bad is essential for Bcl-xL-enhanced Bax shuttling between mitochondria and cytosol,2022-12-29,DOI:10.1016/j.biocel.2022.106359,(IF:5.6)
9、 Ting Xu; Xuxu Li; Tian Leng; Tianchi Zhuang; Yan Sun; Yajun Tang; Li Wang; Muyi Yang; Minghui Ji,CYP2A13 acts as the main metabolic CYP450s enzyme for activating leonurine in human bronchial epithelial cells,2020-1-1,DOI:10.12659/MSM.922149,(IF:2.2)
10、 Odin Zhang; Yufei Huang; Shichen Cheng; Mengyao Yu; Xujun Zhang; Haitao Lin; Yundi Zeng; Mingyang Wan; Zhenxing Wu; Huifeng Zhao; Zaixi Zhang; Chenqi Hua; Yu Ka; Sunliang Cui; Peichen Pan; Yu Hsieh; Tingjun Hou,FragGen: towards 3D geometry reliable fragment-based molecular generation,2024-10-16,DOI:10.1039/d4sc04620j,(IF:7.6)
11、 Donghu Zhou;Siyu Jia;Liping Yi;Zhen Wu;Yi Song;Bei Zhang;Yanmeng Li;Xiaoxi Yang;Anjian Xu;Xiaojin Li;Wei Zhang;Weijia Duan;Zhenkun Li;Saiping Qi;Zhibin Chen;Qin Ouyang;Jidong Jia;Jian Huang;Xiaojuan Ou;Hong You,Identification of potential modifier genes in Chinese patients with Wilson disease,2025-2-21,DOI:10.1093/mtomcs/mfac024,(IF:2.9)
12、 Jing Li; Mimi Chen; Dingwen Huang; Ziyin Li; Yuanqun Chen; Jinhua Huang; Zhili Zhou; Zhiying Yu,Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer,2024-1-12,DOI:10.1002/mco2.70033,(IF:10.7)
13、 Zhongkai Wu;Lilong Zhang;Xinyi Li;Li Liu;Tianrui Kuang;Zhendong Qiu;Wenhong Deng;Weixing Wang,The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma,2024-4-22,DOI:10.1038/s41598-024-60342-w,(IF:3.8)
14、 Yang Bcdef; Gu; Wei Hou; Xin-Yu Bcde; Shen; Bcdf Shi-Xuan; Zhuo Bcf; Hao-Ran Zhang; Bcf Ming-Hui; Ji Adg; Mei-Juan Chen; Abdeg Yuan-Yuan Guo; Yang Gu,CYP2C9, a metabolic CYP450s enzyme, plays critical roles in activating ellagic acid in human intestinal epithelial cells,2020-1-28,DOI:10.12659/MSM.923104,(IF:2.2)
15、 Xue-Dong Yu;Qi-Ya Zhang;Fei Ke,Crispr/Cas13d Mediated Inhibition of Siniperca Chuatsi Rhabdovirus Infection in Fish Cells,2025-02-27,DOI:,(IF:3.9)
16、 Fengguang Zhai; Yuxuan Li; Xia Luo; Xiaofeng Jin; Meng Ye,NOLC1 was identified as a tumor suppressor gene in thyroid cancer and correlated with prognosis by bioinformatics,2024-5-15,DOI:10.62347/iyvv7581,(IF:3.6)
17、 Bo Zhai; Yang Zhou; Hui Yan; Qiang Zhou; Penggao Wang; Fang Yang; Ziqiao Yuan; Yunjiang Zhou,CCNB1IP1 stabilizes MYCN through suppression of Fbxw7-mediated degradation and facilitates the growth of MYCN-amplified neuroblastoma,2022-7-28,DOI:10.21203/rs.3.rs-1876730/v1,(IF:preprint)
18、 Zhongkai Wu;Lilong Zhang;Xinyi Li;Li Liu;Tianrui Kuang;Zhendong Qiu;Wenhong Deng;Weixing Wang,The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma,2024-4-22,DOI:10.1038/s41598-024-60342-w,(IF:3.8)
19、 Hui Xiang; Miao Wang; Yi-Fang Chen; Hao-Ming Wu; Ming-Ge Li; Lei Guo; Ying-Yi Zhang; He-Zhe Lu,Regulation of cancer cell Ferroptosis by PTRF/Cavin-1,2024-1-24,DOI:10.1080/10715762.2024.2386457,(IF:3.6)
20、 Kexin Yan;Simeng Feng;Jiahao Cheng;Fan Zheng;Zhiqiang Li;Zhibang Deng;Xiaomin Yuan,IFITM3 is a host restriction factor that inhibits porcine transmissible gastroenteritis virus infection,2022-12-9,DOI:10.1016/j.vetmic.2022.109622,(IF:2.4)

Plasmid Elements

polyA_site      1048..1442
                     /note="人类β-珠蛋白多聚腺苷酸信号"
     ori      complement(1952..2540)
                     /direction=LEFT
                     /note="高拷贝数 ColE1/pMB1/pBR322/pUC 复制起点"
     AmpR             complement(2711..3571)
                     /codon_start=1
                     /gene="bla"
                     /product="beta-lactamase"
                     /note="赋予对氨苄青霉素、卡那霉素和相关抗生素的抗性。"
                     /translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYI
                     ELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVEYS
                     PVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRW
                     EPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSA
                     LPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGAS
                     LIKHW"
     AmpR promoter        complement(3572..3676)
                     /gene="bla"
     CMV enhancer        3867..4246
                     /note="人类巨细胞病毒即刻早期增强子"
     CMV promoter        4247..4450
                     /note="人类巨细胞病毒(CMV)即刻早期启动子"
     intron          4584..5059
                     /note="来自人类β-珠蛋白的内部截短型内含子"
     VSV-G             join(5134..5822,1..847)
                     /codon_start=1
                     /product="vesicular stomatitis virus G glycoprotein"
                     /note="印第安纳株"
                     /translation="MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSD
                     LNWHNDLIGTALQVKMPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPS
                     VEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQ
                     FINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFR
                     SNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQT
                     SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLK
                     YFETRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPYEDVEIGPNGVLRTSSGYKFP
                     LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWF
                     SSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK"
Previous:pVSV-G
Next:psPAX2
×

Plasmid Sequence

×
(Some plasmids are not full-length sequences)